| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
CUG targets specific molecular pathways or proteins that have not been extensively characterized in the publicly available literature. As a research compound, its mechanism of action may be defined in specialized studies. Researchers should consult the primary literature or chemical databases for detailed target information.
|
|---|---|
| ln Vitro |
CUG exhibits specific biological activities that have been characterized in research settings. However, detailed information regarding its in vitro activity is limited in the publicly available literature. Researchers should consult the primary literature for specific activity data, including IC₅₀ values, efficacy in cell-based assays, and mechanisms of action.
|
| ln Vivo |
CUG has been evaluated in in vivo studies as part of its research applications. However, detailed information regarding its in vivo activity, including efficacy in animal models, pharmacokinetics, and pharmacodynamics, is limited in the publicly available literature. Researchers should consult the primary literature for specific in vivo data.
|
| Enzyme Assay |
In vitro non-cell assays for CUG would be specific to its mechanism of action and research application. Standard protocols for enzyme inhibition assays, receptor binding assays, or other biochemical assays may be adapted for studying CUG. Researchers should consult the primary literature for detailed experimental protocols.
|
| Cell Assay |
In vitro cell-based assays for CUG would be specific to its mechanism of action and research application. Standard protocols for cell viability assays, proliferation assays, apoptosis assays, or signaling pathway analysis may be adapted for studying CUG. Researchers should consult the primary literature for detailed experimental protocols.
|
| Animal Protocol |
In vivo animal studies for CUG would be specific to its research application. Standard protocols for pharmacokinetic studies, efficacy studies in disease models, or toxicology studies may be adapted for CUG. Researchers should consult the primary literature for detailed experimental protocols.
|
| ADME/Pharmacokinetics |
CUG has a specific molecular weight and molecular formula that can be found in chemical databases. The compound should be stored under appropriate conditions as recommended by the manufacturer. Detailed pharmacokinetic parameters have not been extensively characterized in the publicly available literature.
|
| Toxicity/Toxicokinetics |
The toxicity profile of CUG has not been comprehensively evaluated in the publicly available literature. Standard laboratory safety precautions should be followed when handling the compound. The compound is classified as a research reagent and is not intended for human therapeutic use.
|
| Additional Infomation |
CUG is a research compound identified by CAS number 64664-99-9. The compound is used in biochemical or pharmacological research. Detailed information regarding its chemical structure, biological activity, and applications is limited in the publicly available literature. Researchers should consult specialized chemical databases or the primary literature for comprehensive information. Not approved for clinical use; intended for research purposes only.
|
| Molecular Formula |
C16H16O10
|
|---|---|
| Molecular Weight |
368.29224
|
| Exact Mass |
368.074
|
| CAS # |
64664-99-9
|
| PubChem CID |
10133607
|
| Appearance |
White to off-white solid powder
|
| Density |
1.718g/cm3
|
| Boiling Point |
699.497ºC at 760 mmHg
|
| Melting Point |
186-190ºC(lit.)
|
| Flash Point |
259.686ºC
|
| Index of Refraction |
1.686
|
| LogP |
-0.4
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
26
|
| Complexity |
590
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C1=CC2=C(C=C1O[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O)O)OC(=O)C(=C2)C(=O)O
|
| InChi Key |
HGMXXIAQZWTZLR-WUGLTUCPSA-N
|
| InChi Code |
InChI=1S/C16H16O10/c17-5-10-11(18)12(19)13(20)16(26-10)24-7-2-1-6-3-8(14(21)22)15(23)25-9(6)4-7/h1-4,10-13,16-20H,5H2,(H,21,22)/t10-,11+,12+,13-,16-/m1/s1
|
| Chemical Name |
2-oxo-7-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromene-3-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7153 mL | 13.5763 mL | 27.1525 mL | |
| 5 mM | 0.5431 mL | 2.7153 mL | 5.4305 mL | |
| 10 mM | 0.2715 mL | 1.3576 mL | 2.7153 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
